Form 4: NextCure CFO Steven P. Cobourn Acquires 93,900 Employee Stock Options

NextCure's CFO, Steven P. Cobourn, reported the acquisition of 93,900 employee stock options on March 29, 2024.

Summary

• Steven P. Cobourn, the Chief Financial Officer of NextCure, Inc., filed a Form 4 with the SEC on April 2, 2024.
• The filing reports a transaction that occurred on March 29, 2024, where Cobourn acquired 93,900 employee stock options.
• These options have an exercise price of $2.23 and vest fully on March 29, 2025.
• The options expire on March 28, 2034.
• Following the reported transaction, Cobourn directly owns 93,900 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. The acquisition of options by an executive is generally viewed as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership of securities by a company insider. It's common for executives to receive stock options as part of their compensation package.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates